Detection of HER2 through Antibody Immobilization Is Influenced by the Properties of the Magnetite Nanoparticle Coating

被引:7
|
作者
Villegas-Serralta, Enrique [1 ]
Zavala, Oscar [2 ]
Alejandro Flores-Urquizo, Israel [3 ]
Garcia-Casillas, Perla E. [1 ]
Chapa Gonzalez, Christian [1 ]
机构
[1] Univ Autonoma Ciudad Juarez, Inst Ingn & Tecnol, Ciudad Juarez, Chih, Mexico
[2] Univ Autonoma Ciudad Juarez, Inst Ciencias Biomed, Ciudad Juarez, Chih, Mexico
[3] Univ Autonoma Nuevo Leon, Fac Ciencias Quim, San Nicolas De Los Garza, NL, Mexico
关键词
BREAST-CANCER; ALBUMIN;
D O I
10.1155/2018/7571613
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Considerable effort has been focused on improving the control of size, shape, and surface modifications to detect proteins. The purpose of this study was to compare the efficiencies of aminosilane-coated magnetite (As-M) nanoparticles (NPs), dextran-coated magnetite nanoparticles (Dx-M), and bare nanoparticles for conjugating single-chain variable fragment antibodies (scFvs) with the aim of detecting the human epidermal growth factor receptor 2 (HER2) protein. Dx-M and As-M NPs were characterized using scanning electron microscopy, energy dispersive X-ray spectroscopy, X-ray diffraction, and Raman spectroscopy. Dx-M and As-M were conjugated with a monoclonal scFv for active targeting of the HER2 antigen. Aminosilane surface coating enhanced the scFv conjugation efficiency over twofold compared to that of the dextran-coated magnetite NPs for the detection of HER2 proteins.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers
    Hamblett, K. J.
    Barnscher, S. D.
    Davies, R. H.
    Hammond, P. W.
    Hernandez, A.
    Wickman, G. R.
    Fung, V. K.
    Ding, T.
    Garnett, G.
    Galey, A. S.
    Zwierzchowski, P.
    Clavette, B. C.
    Winters, G. C.
    Rich, J. R.
    Rowse, G. J.
    Babcook, J. S.
    Hausman, D.
    CANCER RESEARCH, 2019, 79 (04)
  • [22] HER2 antibody-cytotoxic drug conjugate is the promising targeted therapy for HER2 overexpressing bladder cancer
    Ohara, Shinya
    Hayashi, Tetsutaro
    Sekino, Yohei
    Goto, Keisuke
    Shinmei, Shunsuke
    Teishima, Jun
    Matsubara, Akio
    Sentani, Kazuhiro
    Oue, Naohide
    Yasui, Wataru
    CANCER SCIENCE, 2021, 112 : 839 - 839
  • [23] HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
    Alberto Ocaña
    Eitan Amir
    Atanasio Pandiella
    Breast Cancer Research, 22
  • [24] HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
    Ocana, Alberto
    Amir, Eitan
    Pandiella, Atanasio
    BREAST CANCER RESEARCH, 2020, 22 (01)
  • [25] Antibody Drug Conjugate Targeted Radiosensitization of HER2 Tumors
    Advani, S. J.
    Yang, H.
    Doan, M.
    Camargo, M. F.
    Aguilera, J.
    Adams, S. R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : S148 - S148
  • [26] Construction and characterization of a new chimeric antibody against HER2
    Amiri, Mohammad Mehdi
    Jeddi-Tehrani, Mahmood
    Kazemi, Tohid
    Bahadori, Motahareh
    Maddah, Mahshid
    Hojjat-Farsangi, Mohammad
    Khoshnoodi, Jalal
    Rabbani, Hodjatallah
    Shokri, Fazel
    IMMUNOTHERAPY, 2013, 5 (07) : 703 - 715
  • [27] How can the varied tumour FFPE blocks with HER2 ultra-low influenced on the accurate diagnosis of HER2 in breast cancer
    Liu, Y.
    Li, J.
    Liu, H.
    Ding, Y.
    Wu, S.
    Shang, J.
    VIRCHOWS ARCHIV, 2024, 485 : S1 - S1
  • [28] FDA approves first HER2 x HER3 bispecific antibody
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2025, 24 (02) : 83 - 83
  • [29] HER2 as marker for the detection of circulating tumor cells
    Mueller, Volkmar
    Pantel, Klaus
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 117 (03) : 535 - 537
  • [30] Method of detection of DCIS to predict HER2 overexpression
    Schrading, S.
    Wardelmann, E.
    Kuhn, W.
    Schild, H. H.
    Kuhl, C. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)